Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
JSR Life Sciences to Transfer Crown Bioscience to Adicon Holdings Limited

JSR Life Sciences to Transfer Crown Bioscience to Adicon Holdings Limited

by | Nov 13, 2025 3:04 pm | Biotechnology, Private Equity

JSR Life Sciences LLC, a global leader in life sciences materials and services, announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. to Adicon Holdings Limited. The deal will enable Crown Bioscience to operate as a standalone entity under Adicon’s ownership. The transaction, subject to customary closing conditions, is expected to close in 2026. Financial terms were not disclosed. Crown Bioscience is a contract research organization (CRO) specializing in oncology and immuno-oncology drug discovery and development. The company has a comprehensive portfolio of translational oncology services, including its patient-derived xenograft models, tumor... Read More »
GSK Acquires Syndivia’s Preclinical Antibody Drug Conjugate for More than $357 Million 

GSK Acquires Syndivia’s Preclinical Antibody Drug Conjugate for More than $357 Million 

by | Oct 31, 2025 10:11 am | Biotechnology

GSK Plc announced on October 29 that it acquired Syndivia’s preclinical antibody-drug conjugate (ADC).  Syndivia’s preclinical ADC is in development for the treatment of prostate cancer. Syndivia developed the prostate cancer drug hopeful using its GeminiMab conjugation technology, which the biotech claims can create a unique drug-to-antibody ratio hinge region site-specific ADC.  Syndivia is a French biotechnology company focused on the design and development of ADCs. Its proprietary technology enables the creation of next-generation ADCs with optimized therapeutic profiles, aiming to expand treatment options for patients with cancer.  GSK, formerly... Read More »
TransCode Therapeutics Acquires Polynoma 

TransCode Therapeutics Acquires Polynoma 

by | Oct 9, 2025 2:35 pm | Biotechnology

TransCode Therapeutics, Inc. announced on October 8 that it entered into an agreement to acquire Polynoma LLC.  Polynoma is a privately held biotechnology immuno-oncology company. Polynoma is developing a late-stage candidate, seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma.  TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which... Read More »
TransCode Therapeutics Acquires Polynoma 

Pfizer Buys Metsera and its Next-Generation Obesity Portfolio

by | Sep 24, 2025 10:15 am | Biotechnology

Pfizer Inc. and Metsera, Inc. jointly today announced on September 22 that the companies have entered into a definitive agreement under which Pfizer will acquire Metsera. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Metsera common stock for $47.50 per share in cash at closing, for an initial enterprise value of $4.9 billion with a contingent value right of up to $22.50 per share in additional payments. The Boards of Directors of both Metsera and Pfizer have unanimously approved the transaction, which is expected to close in the fourth quarter of 2025. Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for... Read More »
Kite Acquires Interius BioTherapeutics to Advance In Vivo Platform

Kite Acquires Interius BioTherapeutics to Advance In Vivo Platform

by | Aug 21, 2025 10:58 am | Biotechnology

Kite Pharma, a wholly owned subsidiary of Gilead Sciences, announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics for a total of $350 million in cash consideration. Interius BioTherapeutics is a clinical-stage biotechnology company engineering targeted, programmable vectors for the precision delivery of genetic medicines to treat an array of challenging diseases in oncology, autoimmunity and beyond. Leveraging a proprietary platform, Interius has created a differentiated off-the-shelf therapeutic modality designed for broad patient access. The company’s lead programs aim to overcome the current limitations of ex vivo chimeric antigen receptor (CAR)... Read More »
TransCode Therapeutics Acquires Polynoma 

Concentra Biosciences Acquires iTeos Therapeutics for $434 Million 

by | Jul 21, 2025 2:09 pm | Biotechnology

Concentra Biosciences, LLC announced that it entered into an agreement to acquire iTeos Therapeutics for more than $434.4 million.  iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. According to iTeos Therapeutics’ financial reports, the company reported $35 million in revenue for the full year 2024.  Concentra Biosciences is owned by Tang Capital... Read More »